Role of Opioidergic System in Regulating Depression Pathophysiology

Author(s): George Anderson*, Michael Maes

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 41 , 2020


Become EABM
Become Reviewer
Call for Editor

Abstract:

Background: There is a clear clinical need for a better understanding of the biological underpinnings of major depressive disorder (MDD), allowing for the development of a treatment that is targeted to pathophysiology. Recent data indicate a role for the endogenous opioidergic system in MDD. This article reviews the roles and physiological interactions of the endogenous opioidergic system in the pathophysiology and heterogeneity of MDD.

Methods: Articles on the pathophysiology of MDD, as well as on the endogenous opioidergic system and mitochondrial function, form the basis of this review article.

Results: The endogenous opioidergic system is intimately linked to wider MDD pathophysiology, including alterations in the gut microbiome, gut permeability, circadian rhythm, amygdala-prefrontal cortex interactions, and mitochondrial function. A decrease in the μ-/κ-opioid receptor ratio is an important mediator of the changes in mood in MDD, with effects not only on neurons, but also on glia and immune cells.

Conclusion: The endogenous opioidergic system is intimately interwoven with MDD pathophysiology and provides a relevant target for novel treatment development, as well as providing a focus for the integration of wider MDD pathophysiology.

Keywords: Depression, mitochondria, endogenous opioids, amygdala, gut dysbiosis, circadian rhythm, ceramide, melatonin, LPS, inflammation.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 41
Year: 2020
Published on: 12 December, 2020
Page: [5317 - 5334]
Pages: 18
DOI: 10.2174/1381612826666200806101744
Price: $65

Article Metrics

PDF: 18